Clinical Trial Update: Phase II, Open Label, Non-randomized, Trial of BKM120 for Metastatic or Locally Advanced Cervical Cancer [Phase 2]

View source ↗

Summary

A Phase II, open-label, non-randomized trial of BKM120 (buparlisib) for metastatic or locally advanced cervical cancer has been withdrawn. The sponsor is Novart…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• BKM120 (Buparlisib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Treatment for Metastatic or Locally Advanced Cervical Cancer | Phase 2 | Status: WITHDRAWN